Volume 18 Supplement 1

19th Annual SCMR Scientific Sessions

Open Access

T1 mapping for characterization of myocardial fibrosis in hypertrophic cardiomyopathy

  • Ying Liu1,
  • Shun Qi1,
  • Zhankui Wang1,
  • Jianmin Zheng1,
  • Tianjing Zhang2,
  • Andreas Greiser3 and
  • Hong Yin1
Journal of Cardiovascular Magnetic Resonance201618(Suppl 1):P320


Published: 27 January 2016


It was reported that the occurrence of myocardial fibrosis was related to sudden cardiac death and heart failure in patients with HCM. Late gadolinium enhancement (LGE) magnetic resonance imaging (MRI) is a widely used clinical method to detect fibrosis, however, its spatial resolution is limited. The purpose of this feasibility study is to determine the value of T1 mapping for the non-invasive assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy (HCM).


Thirty HCM patients and 20 healthy volunteers underwent conventional late gadolinium enhancement (LGE) imaging and T1 mapping (Siemens prototype sequence) on a clinical 1.5T scanner (MAGNETOM Aera, Siemens Healthcare). T1 mapping was performed with a modified look-locker inversion-recovery (MOLLI) sequence acquired during breath hold in the same planes after LGE imaging. Typical imaging parameters were: non-selective inversion pulse, steady-state free precession single-shot read out in mid-diastole, FOV of 360 × 250 mm2, matrix of 192 × 150, slice thickness of 8 mm, TR/TE of 375.28/1.01 ms, minimum inversion time of 90 ms, inversion time increment of 80 ms, FA of 35?, PAT factor of 2, number of inversions 2, images acquired after first inversion 3, pause 3 heart beats, and images acquired after second inversion. T1 Mapping was used for measurement of T1 values. Global ECV values were calculated from T1 maps acquired pre- and post-contrast calibrated by blood hematocrit. The extracellular volume (ECV) value was calculated as: ECV = (1-hematocrit) (1/T1myopost-1/T1myopre) / (1/T1bloodpost-1/T1bloodpre).


HCM patients had the same age as control group (38.2 ± 18.5 vs. 34.8 ± 15.7, P=NS). Pre-contrast myocardial T1 time and myocardial ECV in patients with HCM was significantly higher than the measurement in control cases, and post-contrast myocardial T1 time in HCM patients was significantly lower than that in control cases (P < 0.05, respectively) (Table 1, Figure 1).
Table 1

T1 measurement and ECV in cases with HCM and in control cases

Mapping parameters



P value

Pre-contrast T1 value

1217.3 ± 97.4

1143.6 ± 84.3


Post-contrast T1 value

489.3 ± 57.1

503.1 ± 64.4



0.257 ± 0.036

0.231 ± 0.028


Figure 1


The MOLLI T1 mapping used in the present study has combined the fast acquisition time and multiple contrast capabilities of the TI scout with the improved CNR, spatial resolution, and spatial coverage of the segmented IR LGE scans. The combination reduces the total imaging time, enables T1 quantification, and does not compromise image quality. A relatively higher pre-contrast T1 value and ECV, and lower post-contrast T1 value were found with T1 mapping in the myocardium of HCM patients, which suggested T1 mapping is better in the evaluation of myocardial fibrosis. The main limitation is that we had a small patient population without subgroup analysis and follow-up.

Authors’ Affiliations

Dept. of Radiology, Xijing Hospital, Fourth Military Medical University
Siemens Healthcare, MR Collaborations NE Asia
Siemens Healthcare


© Liu et al. 2016

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.